GastroEsophageal Reflux Disease

This study consists of 2 parts. A multi-center, short-term, double-blind, randomized, parallel group

study (Part 1), and a long-term, double-blind, maintenance study (Part 2) in pediatric subjects 1 to

11 years of age with endoscopically proven GERD. In Part 1, the study will consist of 3 phases: a

14-day screening phase, a double-blind treatment phase of 12 weeks, and an end-of-study or early

withdrawal phase followed by Part 2, which consists a of double-blind treatment continuation for

subjects who achieved healing

(grade 0 on the Hetzel and Dent classification or grade 0 on the

Histological Features of Reflux Esophagitis scale) during the short-term double-blind treatment phase

The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).

The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics and safety of rabeprazole after single and multiple daily administration in infants between the ages of 1 and 11 months, inclusive, with GERD.

The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).

The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).